Humoral Response and Tolerance of Vaccination against SARS-CoV-2 in Adults Senegalese Patients Undergoing Hemodialysis: A Multicenter Prospective Study
Introduction: Following the COVID-19 pandemic, vaccination has been proposed in several countries as the main preventive measure despite very limited data, particularly in dialysis patients. We conducted this study to assess the immunological response to vaccination in Senegalese hemodialysis patients. Patients and Methods: We conducted a prospective study, in two dialysis centers in Dakar from March 30th to August 30th, 2021 including patients on hemodialysis for >6 months, vaccinated against SARS-CoV-2 according to the vaccination schedule recommended by WHO. A vaccine response was considered positive when seroconversion was observed after one dose of vaccine. The clinical efficacy of immunization was defined as the absence of new COVID-19 infection in patients who received a complete vaccination. Results: Among the 81 patients included in the study, 7.4% had anti-Spike IgM antibodies before their first vaccination. Seroprevalence of IgM antibodies was 38.3% one month after the first vaccine dose (at M1) and 8.6% one month after the second dose (at M4). Anti-Spike IgG antibodies were present in 40.3% of patients before vaccination, in 90.1% at M1, and in 59.7% at M4. Among patients previously infected with SARS-CoV-2, 10.2% had IgM antibodies at M0, 31.6% at M1, and 10.5% at M4 post-vaccination. Similarly, seroprevalences of IgG antibodies in this subgroup were 31.5%, 61.3%, and 50.0% respectively at M0, M1, and M4 post-vaccination. A comparison of seroconversion rates between M0 and M4 showed significant differences only for IgG in COVID-19 naive patients. Mean duration in dialysis and the existence of previous COVID-19 infection were associated with patients’ vaccinal response after the two doses. Age, gender and the use of immunosuppressive treatment did not influence post-vaccinal antibody production. Conclusion: Vaccination against COVID-19 in Senegalese hemodialysis patients induced a low seroconversion rate but it was well tolerated. Moreover, the induced protection was neither strong nor durable, particularly in patients with longer duration in dialysis.
References
[1]
World Health Organization, Regional Office for Africa (2022) COVID-19 Response for Africa-Monthly Bulletin COVID: Situation and Response Actions in the African Region. https://iris.who.int/bitstream/handle/10665/363500/IMST-COVID-19202209-eng.pdf?sequence=1&isAllowed=y
[2]
Francis, A., Baigent, C., Ikizler, T.A., Cockwell, P. and Jha, V. (2021) The Urgent Need to Vaccinate Dialysis Patients against Severe Acute Respiratory Syndrome Coronavirus 2: A Call to Action. Kidney International, 99, 791-793. https://doi.org/10.1016/j.kint.2021.02.003
[3]
Zheng, W., Yan, X., Zhao, Z., et al. (2021) COVID-19 Vaccination Program in the Mainland of China: A Subnational Descriptive Analysis on Target Population Size and Current Progress. Infectious Diseases of Poverty, 10, Article 124. https://doi.org/10.1186/s40249-021-00909-1
[4]
Shahcheraghi, S.H., Ayatollahi, J., Aljabali, A.A., et al. (2021) An Overview of Vaccine Development for COVID-19. Therapeutic Delivery, 12, 235-244. https://doi.org/10.4155/tde-2020-0129
[5]
Ba, M.F., Faye, A., Kane, B., et al. (2022) Factors Associated with COVID-19 Vaccine Hesitancy in Senegal: A Mixed Study. Human Vaccines and Immunotherapeutics, 18, Article 2060020. https://doi.org/10.1080/21645515.2022.2060020
[6]
Ren, P., Yu, M., Shen, X., et al. (2022) Immunogenicity and Safety of SARS-CoV-2 Vaccine in Hemodialysis Patients: A Systematic Review and Meta-Analysis. Frontiers in Public Health, 10, Article 951096. https://doi.org/10.3389/fpubh.2022.951096
[7]
National Center for Immunization and Respiratory Diseases (NCIRD) and Division of Viral Diseases (2021) Science Brief: SARS-CoV-2 Infection-Induced and Vaccine-Induced Immunity. Centers for Disease Control and Prevention Atlanta, GA.
[8]
Kolb, T., Fischer, S., Müller, L., et al. (2021) Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and Kidney Transplant Recipients. Kidney360, 2, 1491-1498. https://doi.org/10.34067/KID.0003512021
[9]
Raja, N., Rajagopalan, A., Arunachalam, J., Prasath, A., Durai, R. and Rajendran, M. (2022) Humoral Response to Viral Vector COVID-19 Vaccine in Hemodialysis Patients. Kidney Research and Clinical Practice, 41, 342-350. https://doi.org/10.23876/j.krcp.21.184
[10]
Chan, L., Fuca, N., Zeldis, E., Campbell, K.N. and Shaikh, A. (2021) Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in Hemodialysis Patients with and without Prior COVID-19. Clinical Journal of the American Society of Nephrology, 16, 1258-1260. https://doi.org/10.2215/CJN.04080321
[11]
Billany, R.E., Selvaskandan, H., Adenwalla, S.F., Hull, K.L., March, D.S., Burton, J.O., et al. (2021) Seroprevalence of Antibody to S1 Spike Protein Following Vaccination against COVID-19 in Patients Receiving Hemodialysis: A Call to Arms. Kidney International, 99, 1492-1494. https://doi.org/10.1016/j.kint.2021.04.008
[12]
Attias, P., Sakhi, H., Rieu, P., Soorkia, A., Assayag, D., Bouhroum, S., et al. (2021) Antibody Response to the BNT162b2 Vaccine in Maintenance Hemodialysis Patients. Kidney International, 99, 1490-1492. https://doi.org/10.1016/j.kint.2021.04.009
[13]
Torreggiani, M., Blanchi, S., Fois, A., Fessi, H. and Piccoli, G.B. (2021) Neutralizing SARS-CoV-2 Antibody Response in Dialysis Patients after the First Dose of the BNT162b2 mRNA COVID-19 Vaccine: The War is Far From Being Won. Kidney International, 99, 1494-1496. https://doi.org/10.1016/j.kint.2021.04.010
[14]
Gobbi, F., Buonfrate, D., Moro, L., Rodari, P., Piubelli, C., Caldrer, S., et al. (2021) Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses, 13, Article 422. https://doi.org/10.3390/v13030422
[15]
Seck, S., Ka, F. and Cisse, M. (2014) Enquête de prévalence de la maladie rénale chronique dans la région Nord du Sénégal. Néphrologie and Thérapeutique, 10, 399. https://doi.org/10.1016/j.nephro.2014.07.128
[16]
Müller, L., Andrée, M., Moskorz, W., et al. (2021) Age-Dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clinical Infectious Diseases, 73, 2065-2072. https://doi.org/10.1093/cid/ciab381
Richards, N.E., Keshavarz, B., Workman, L.J., et al. (2021) Comparison of SARS-CoV-2 Antibody Response by Age among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine. JAMA Network Open, 4, e2124331. https://doi.org/10.1001/jamanetworkopen.2021.24331
[19]
Seck, S.M., Mbow, M., Kane, Y., et al. (2021) Prevalence of SARS-CoV-2 Antibodies in Hemodialysis Patients in Senegal: A Multicenter Cross-Sectional Study. BMC Nephrology, 22, Article No. 384. https://doi.org/10.1186/s12882-021-02582-w
[20]
Agur, T., Ben-Dor, N., Goldman, S., Lichtenberg, S., Herman-Edelstein, M., Yahav, D., et al. (2021) Antibody Response to mRNA SARS-CoV-2 Vaccine among Dialysis Patients—A Prospective Cohort Study. Nephrology Dialysis Transplantation, 36, 1347-1349.
[21]
Michael, P., Arend, F.M., Hasmann, S., Lau, T., et al. (2021) Anti-body Response to mRNA SARS-CoV-2 Vaccines in Hemodialysis Patients. Clinical Kidney Journal, 14, 2234-2238.
[22]
Anand, S., Montez-Rath, M.E., Han, J., Garcia, P., Cadden, L., Hunsader, P., et al. (2021) Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis. Journal of the American Society of Nephrology, 32, 2435-2438. https://doi.org/10.1681/ASN.2021050611
[23]
Stumpf, J., Schwöbel, J., Lindner, T., et al. (2022) Risk of Strong Antibody Decline in Dialysis and Transplant Patients after SARS-CoV-2mRNA Vaccination: Six Months Data from the Observational Dia-Vacc Study. The Lancet Regional Health—Europe, 17, Article 100371. https://doi.org/10.1016/j.lanepe.2022.100371
[24]
Simon, B., Rubey, H., Treipl, A., Gromann, M., Hemedi, B., Zehetmayer, S., et al. (2021) Hemodialysis Patients Show a Highly Diminished Antibody Response after COVID-19 mRNA Vaccination Compared with Healthy Controls. Nephrology Dialysis Transplantation, 36, 1709-1716. https://doi.org/10.1093/ndt/gfab179
[25]
Füessl, L., Lau, T., Lean, I., et al. (2022) Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients. Vaccines, 10, Article 605. https://doi.org/10.3390/vaccines10040605
[26]
El Karoui, K., Hourmant, M., Ayav, C., Glowacki, F., Couchoud, C., Lapidus, N., et al. (2022) Vaccination and COVID-19 Dynamics in Dialysis Patients. Clinical Journal of the American Society of Nephrology, 17, 395-402. https://doi.org/10.2215/CJN.10300721
[27]
Zong, K., Peng, D., Yang, H., et al. (2022) Risk Factors for Weak Antibody Response of SARS-CoV-2 Vaccine in Adult Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis. Frontiers in Immunology, 13, Article 888385. https://doi.org/10.3389/fimmu.2022.888385
[28]
Bert, F., Scaioli, G., Vola, L., Accortanzo, D., et al. (2022) Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries. International Journal of Environmental Research and Public Health, 19, Article 7233. https://doi.org/10.3390/ijerph19127233
[29]
Broseta, J.J., Rodríguez-Espinosa, D., Rodríguez, N., et al. (2021) Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. American Journal of Kidney Diseases, 78, 571-581. https://doi.org/10.1053/j.ajkd.2021.06.002
[30]
Housset, P., Kubab, S., Hanafi, L., et al. (2022) Humoral Response after a Fourth “Booster” Dose of a Coronavirus Disease 2019 Vaccine Following a 3-Dose Regimen of mRNA-Based Vaccination in Dialysis Patients. Kidney International, 101, 1289-1290. https://doi.org/10.1016/j.kint.2022.04.006
[31]
Biedunkiewicz, B., Tylicki, L., Ślizień, W., et al. (2022) Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose. Vaccines, 10, Article 433. https://doi.org/10.3390/vaccines10030433
[32]
Dimeglio, C., Herin, F., Martin-Blondel, G., Miedougé, M. and Izopet, J. (2022) Antibody Titers and Protection against a SARS-CoV-2 Infection. Journal of Infection, 84, 248-288. https://doi.org/10.1016/j.jinf.2021.09.013
[33]
Azzolini, E., Pozzi, C., Germagnoli, L., Oresta, B., Carriglio, N., Calleri, M., et al. (2022) mRNA COVID-19 Vaccine Booster Fosters B- and T-Cell Responses in Immunocompromised Patients. Life Science Alliance, 5, e202201381. https://doi.org/10.26508/lsa.202201381
